Johnson & Johnson Research and Development Expenses 2010-2024 | JNJ
Johnson & Johnson annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Johnson & Johnson research and development expenses for the quarter ending March 31, 2024 were $3.542B, a 0.59% decline year-over-year.
- Johnson & Johnson research and development expenses for the twelve months ending March 31, 2024 were $15.064B, a 5.82% increase year-over-year.
- Johnson & Johnson annual research and development expenses for 2023 were $15.085B, a 6.72% increase from 2022.
- Johnson & Johnson annual research and development expenses for 2022 were $14.135B, a 0.99% decline from 2021.
- Johnson & Johnson annual research and development expenses for 2021 were $14.277B, a 17.42% increase from 2020.
Johnson & Johnson Annual Research and Development Expenses
(Millions of US $) |
| 2023 |
$15,085 |
| 2022 |
$14,135 |
| 2021 |
$14,277 |
| 2020 |
$12,159 |
| 2019 |
$11,355 |
| 2018 |
$10,775 |
| 2017 |
$10,594 |
| 2016 |
$9,143 |
| 2015 |
$9,046 |
| 2014 |
$8,494 |
| 2013 |
$8,183 |
| 2012 |
$7,665 |
| 2011 |
$7,548 |
| 2010 |
$6,844 |
| 2009 |
$6,986 |
Johnson & Johnson Quarterly Research and Development Expenses
(Millions of US $) |
| 2024-03-31 |
$3,542 |
| 2023-12-31 |
$4,246 |
| 2023-09-30 |
$3,447 |
| 2023-06-30 |
$3,829 |
| 2023-03-31 |
$3,563 |
| 2022-12-31 |
$3,485 |
| 2022-09-30 |
$3,485 |
| 2022-06-30 |
$3,703 |
| 2022-03-31 |
$3,462 |
| 2021-12-31 |
$4,283 |
| 2021-09-30 |
$3,422 |
| 2021-06-30 |
$3,394 |
| 2021-03-31 |
$3,178 |
| 2020-12-31 |
$4,032 |
| 2020-09-30 |
$2,840 |
| 2020-06-30 |
$2,707 |
| 2020-03-31 |
$2,580 |
| 2019-12-31 |
$3,232 |
| 2019-09-30 |
$2,599 |
| 2019-06-30 |
$2,666 |
| 2019-03-31 |
$2,858 |
| 2018-12-31 |
$3,224 |
| 2018-09-30 |
$2,508 |
| 2018-06-30 |
$2,639 |
| 2018-03-31 |
$2,404 |
| 2017-12-31 |
$3,643 |
| 2017-09-30 |
$2,585 |
| 2017-06-30 |
$2,296 |
| 2017-03-31 |
$2,070 |
| 2016-12-31 |
$2,688 |
| 2016-09-30 |
$2,178 |
| 2016-06-30 |
$2,264 |
| 2016-03-31 |
$2,013 |
| 2015-12-31 |
$2,864 |
| 2015-09-30 |
$2,154 |
| 2015-06-30 |
$2,129 |
| 2015-03-31 |
$1,899 |
| 2014-12-31 |
$2,635 |
| 2014-09-30 |
$2,023 |
| 2014-06-30 |
$2,005 |
| 2014-03-31 |
$1,831 |
| 2013-12-31 |
$2,411 |
| 2013-09-30 |
$2,042 |
| 2013-06-30 |
$1,946 |
| 2013-03-31 |
$1,784 |
| 2012-12-31 |
$2,331 |
| 2012-09-30 |
$1,923 |
| 2012-06-30 |
$1,766 |
| 2012-03-31 |
$1,645 |
| 2011-12-31 |
$2,155 |
| 2011-09-30 |
$1,773 |
| 2011-06-30 |
$1,882 |
| 2011-03-31 |
$1,738 |
| 2010-12-31 |
$1,982 |
| 2010-09-30 |
$1,657 |
| 2010-06-30 |
$1,648 |
| 2010-03-31 |
$1,557 |
| 2009-12-31 |
$2,213 |
| 2009-09-30 |
$1,617 |
| 2009-06-30 |
$1,638 |
| 2009-03-31 |
$1,518 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$353.804B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
